Eisai Sets Sliding-Scale Discounts For India Launch Of Breast-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai says it has developed a sliding-scale pricing system to use when it launches its Halaven (eribulin) breast-cancer drug in India this fall.